Sam­sung adds an­oth­er Lu­cen­tis in­ter­change­able biosim­i­lar to the mix

The FDA ear­li­er this month signed off on an­oth­er in­ter­change­able biosim­i­lar, one of just a hand­ful to date, this time to Sam­sung Bioepis for its oph­thal­mol­o­gy drug that’s in­ter­change­able with Roche’s block­buster Lu­cen­tis (ranibizum­ab).

The ap­proval of Sam­sung’s By­ooviz (ranibizum­ab-nuna) is the sec­ond FDA ap­proval for an in­ter­change­able to Lu­cen­tis, with the first com­ing to Co­herus Bio­Sciences’ Cimer­li (ranibizum­ab-eqrn) last Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER